Understanding the role of tau and amyloid proteins in Alzheimer’s disease is essential to the development of potential treatments. We’re breaking down the complexity of tau on our new website, KnowTau.com, to help researchers and healthcare professionals better understand what is currently known about this protein’s role in Alzheimer’s disease. Learn more:
About us
Founded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patients’ lives and to create value for shareholders and our communities. We apply deep understanding of human biology and leverage different modalities, to advance first-in-class treatments or therapies that deliver superior outcomes. Our approach is to take bold risks, balanced with return on investment to deliver long-term growth. With approximately 7,000 people worldwide, we are truly a global organization, headquartered in Cambridge, Massachusetts, which is also home to our research operations. Our international headquarters are based in Baar, Switzerland and we have world-class manufacturing facilities in North Carolina and Solothurn, Switzerland. We offer therapies globally through direct affiliate presence in 30 countries and a network of distribution partners in over 50 additional countries. For more information, please visit www.biogen.com. Follow us on social media – LinkedIn, Facebook, X, and YouTube.
- Website
-
http://www.biogen.com
External link for Biogen
- Industry
- Biotechnology Research
- Company size
- 5,001-10,000 employees
- Headquarters
- Cambridge, MA
- Type
- Public Company
Locations
-
Primary
225 Binney Street
Cambridge, MA 02142, US
-
Landis & Gyr-Strasse 3
Zug, CH 6300, CH
-
P.O. Box 14627
5000 Davis Drive
Research Triangle Park, NC 27709, US
Employees at Biogen
-
Bjoern Rosner
Executive Leader | Digital Operations | Biotech | Pharma | Driving product commercialization and digital innovation from conception to deployment…
-
Saleem Hussaini
Business Technology Leader | Life Sciences | @Biogen
-
Frode Hellesnes
-
Stavros Platakis
Global Head Customer Excellence and Operations BBU at Biogen
Updates
-
This Spinal Muscular Atrophy (SMA) Awareness month, Kim shares her passion for adventure and how she is traveling the world with SMA. Kim is inspiring others to pursue their dreams and discusses how she turns challenges into opportunities to experience the best the world has to offer. Hear more of her story and travel advice on our website: https://ow.ly/96Jw50SPea3 #SMAAwarenessMonth | #SMA
-
STARTING SOON: Join our Q2 2024 financial results live webcast at 8:30 AM ET. Join here: https://ow.ly/pwew50SOymX #Earnings | #BIIB | #FinancialResults
-
Through our research on the role of tau in Alzheimer’s disease, we can learn more about the neurological basis of this debilitating disease and how symptoms arise for patients. Learn more about tau’s role in neurodegenerative diseases. #AlzheimersDisease | #AlzheimersResearch | #AAIC24
This content isn’t available here
Access this content and more in the LinkedIn app
-
Teaching hands-on science for neurodivergent students helps us to contribute to a diverse life sciences pipeline. Our RTP CoLab was proud to welcome the Durham Public Schools (DPS)'s NeuroDiversity camp to help foster an environment to explore STEM. We look forward to working with DPS, the Autism Society of North Carolina and the North Carolina Business Committee for Education this Disability Pride Month and beyond. Explore the impact of Biogen’s CoLab: https://ow.ly/GBsT50SOibz #STEMCareers | #DisabilityPrideMonth | #CaringDeeply
-
-
Today we announced a collaboration with Beckman Coulter Diagnostics and Fujirebio Diagnostics, Inc. to identify and develop blood-based biomarkers for tau pathology in the brain. As leaders in Alzheimer's disease (AD) research and development, we aim to advance new tools that can measure brain tau pathology to potentially stratify patients or monitor treatment response in AD clinical trials. Learn more here: https://ow.ly/Btmo50SNxNw #News | #Neuroscience | #AlzheimersDisease
-
The lack of diversity in clinical trials is a challenge that needs to be addressed. At Biogen, we’re working to identify and understand how barriers can impact communities’ participation in clinical trials, and how potentially addressing social determinants of health as related to Alzheimer's disease can help improve diversity in trial enrollment. We look forward to sharing our research and key learnings on this important topic at the Alzheimer’s Association International Conference (AAIC). #AlzheimersDisease | #AlzheimersResearch | #AAIC24
-
-
We’re attending the Alzheimer’s Association International Conference (AAIC) in Philadelphia from July 28th through August 1st. We look forward to connecting with the Alzheimer’s disease (AD) community and sharing the latest data across our portfolio on AD, a complex and debilitating disease impacting millions worldwide. Learn more about our research in AD: https://ow.ly/rIvj50SLm0J #AAIC24 | #Biogen | #AlzheimersResearch
-
Meet the future of STEM! Our RTP CoLab welcomed The Lady Cardinals to explore what’s possible with a career in science. Hosting summer program participants is just one example of our long-standing efforts to build a diverse talent pipeline in North Carolina and beyond. Thanks to North Carolina Department of Commerce Secretary Machelle Baker Sanders, who created this program to drive gender equality in STEM jobs and earnings. Explore the impact of Biogen’s CoLab: https://ow.ly/Es7Q50SKiWx #STEMCareers | #WomenInSTEM | #CaringDeeply
-
-
We’re proud of our very own Rachid Izzar for being named one of the newest members to its Board of Governors for The Alzheimer’s Drug Discovery Foundation. Rachid, along with other key leaders, will work together to lend insights and continue to expand research and advancements to help the Alzheimer’s community. Read more here: https://ow.ly/f17850SKmjt #TeamBiogen | #AlzheimersDisease | #News
-
Affiliated pages
Similar pages
Browse jobs
Stock
BIIB
NASDAQ
20 minutes delay
$207.19
-6.015 (-2.821%)
- Open
- 215.8
- Low
- 206.02
- High
- 219.44
Data from Refinitiv
See more info on